U.S. President Donald Trump’s foreign-imports tariff policies did not hold up well at the Supreme Court, which ruled unconstitutional his edicts under the International Emergency Economic Powers Act. The sharply worded 6-3 opinion was authored by Chief Justice John Roberts. Read More
Japan is backing conditional approvals of Amchepry (raguneprocel, Sumitomo Pharma Co. Ltd./Racthera Co. Ltd.) and Reheart (Cuorips Inc.), positioning them to become the world’s first induced pluripotent stem cell-derived (iPSC) therapies to receive regulatory clearance. Read More
Grail Inc.’s share price dropped more than 50% in premarket trading Feb. 20 after it reported late the day before that the NHS-Galleri trial did not meet its primary endpoint. The U.K study, done though the National Health Service with 142,000 individuals enrolled, evaluated the ability of Grail’s Galleri multicancer early detection test to look for cancer-specific methylation patterns in blood. Read More
Antibiotics specialist Bioversys AG has reported the first clinical proof-of-concept data for alpibectir (BVL-GSK098) in combination with ethionamide in pulmonary tuberculosis, with phase IIa early bactericidal activity data published in the New England Journal of Medicine. Read More
Hand wringing over what support Europe’s biopharma sector needs to stay competitive has intensified since the European Commission unveiled its proposal for an EU Biotech Act in December 2025, and the latest contribution to the debate is a comparative analysis of how 10 countries have strengthened their biopharmaceutical ecosystems post-COVID-19. Read More
U.S. FDA approvals began 2026 at a slower pace than usual, with eight approvals recorded in January. The total falls below the 2025 monthly average of about 19 approvals and trails every month last year, which ranged from 12 to 27 approvals. Read More
New hires and promotions in the biopharma and med-tech industries, including: Artiva, Ataibeckley, Fize, Integrated, Novabridge, Phio, Reacta. Read More
Biopharma and med-tech companies raising money in public or private financings, including: 20/20 Biolabs, Altesa, Compass, Elumn8, Envoy, Eupraxia, Medical 21, Moleculin, Oncopeptides, Resverlogix, Sift, Starget, Ten63. Read More
Clinical updates for biopharma and med tech, including data readouts and publications: Avidity, Merck, Myriad Generics, Traws, Viiv, Yoltech. Read More
Biopharma and med-tech happenings, including deals and partnerships, and other news in brief: Angiodynamics, Briacell, Briapro, Cassava, Catheter Precision, Devonian, Johnson & Johnson, Senseonics, Sequel. Read More
Regulatory snapshots for biopharma and med tech, including global submissions and approvals, and other regulatory decisions and designations: Acrotech, Astrazeneca, Breath Diagnostics, Daiichi, Dror Ortho Design, GE Healthcare, Hansa, Pilatus, Regeneron, Sibel, Skylinedx. Read More
